Peluntamig (PT217) targets DLL3 and CD47, receiving FDA orphan drug and fast track designations for SCLC and NEC. The SKYBRIDGE trial evaluates peluntamig's safety, tolerability, and efficacy in ...

Oxford, UK, San Jose, Calif., 3 rd October 2023 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, ...

Mammalian Notch receptor homologs (Notch1 to 4) encode a Notch extracellular domain (NECD) that binds ligands, a transmembrane domain, and a Notch intracellular domain (NICD) that translocates to the ...

DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...

MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, according to study results presented at ESMO Congress. Delta-like ligand 3 (DLL3) is highly ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage ...

DUBLIN--(BUSINESS WIRE)--The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. Global DLL3 Targeted ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced several regulatory actions. Here is an overview of decisions that may be relevant to your ...

Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...

Antibody–drug conjugates (ADCs) in oncology have been some of the most sought-after assets in the biopharma dealmaking landscape in the past two years. For example, in 2023, Pfizer purchased Seagen, ...

BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein DLL3 was discovered using OBT’s proprietary OGAP® drug discovery platform Fast ...